Drug Trial Radar · NCT02508389
A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
Last checked: Nov 20, 2026Latest source record: Sep 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
223
Actual
Start
Oct 12, 2015
Primary completion
Sep 18, 2017
Study completion Aug 29, 2019
Sponsor
- Lead sponsor
- Galera Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 24, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Supportive care
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the phase 2, GT-201 clinical study is to determine if GC4419 administered prior to intensity-modulated radiation therapy (IMRT) reduces the incidence, duration, and severity of radiation induced oral mucositis in patients who have been diagnosed with locally advanced, non-metastatic squamous cell carcinoma of the head and neck.
Conditions
- Radiation Induced Oral Mucositis
Interventions
Low Dose GC4419: 30mg/dayDrug
Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
High Dose GC4419: 90mg/dayDrug
High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
PlaceboDrug
Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
Intensity-Modulated Radiation TherapyRadiation
Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks
CisplatinDrug
Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses. Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration (in Days) of Radiation Induced Severe Oral Mucositis (OM) Per World Health Organization (WHO) CriteriaTime frame: From start of Intensity-modulated radiation therapy (IMRT) through 8 weeks follow-up, an average of 15 weeks
Locations
64 sites in 3 countries. Site status is shown where the registry gives one.
University of Arizona Cancer Center at Dignity Health St. Joseph's
Phoenix, Arizona
University of Arizona
Tucson, Arizona
Fowler Family Center for Cancer Care
Jonesboro, Arkansas
University of Arkansas for Medical Sciences- Winthrop P. Rockefeller Cancer Institute
Little Rock, Arkansas
VA Long Beach Healthcare System
Long Beach, California
USC Norris Comprehensive Cancer Center
Los Angeles, California
Clinical Trials and Research Associates, Inc.
Montebello, California
UC Irvine Chao Family Comprehensive Cancer Center
Orange, California
Stanford Cancer Institute
Stanford, California
St. Mary's Regional Cancer Center
Grand Junction, Colorado
UConn Health School of Dental Medicine
Farmington, Connecticut
Pasco Pinellas Cancer Center
Holiday, Florida
Lakeland Regional Health Cancer Center
Lakeland, Florida
UF Health Cancer Center at Orlando Health
Orlando, Florida
Sacred Heart Medical Oncology Group
Pensacola, Florida
Northwestern University
Chicago, Illinois
University of Indianan, Goshen Center for Cancer Care
Goshen, Indiana
Department of Radiation Oncology University of Iowa Hospitals & Clinics
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
Ashland-Bellefonte Cancer Center
Ashland, Kentucky
University of Kentucky, Albert B. Chandler Medical Center
Lexington, Kentucky
University of Louisville Hospital, James Graham Brown Cancer Center
Louisville, Kentucky
Tulane Cancer Center
New Orleans, Louisiana
CHRISTUS Schumpert Cancer Treatment Center
Shreveport, Louisiana
Baystate Regional Cancer Program
Springfield, Massachusetts
University of Michigan
Ann Arbor, Michigan
Henry Ford Allegiance Health
Jackson, Michigan
Lake Huron Medical Center
Port Huron, Michigan
Ellis Fichel Cancer Center, University of Missouri
Columbia, Missouri
Billings Clinic
Billings, Montana
St. Vincent Frontier Cancer Center
Billings, Montana
Renown Cancer Institute
Reno, Nevada
Hunterdon Hematology Oncology, LLC Hunterdon Regional Cancer Center
Flemington, New Jersey
Jersey Shore University Medical Center- Hackensack Meridian Health
Neptune City, New Jersey
Montefiore Medical Center
The Bronx, New York
East Carolina University, Leo W. Jenkins Cancer Center
Greenville, North Carolina
Marion L. Shepard Cancer Center
Washington, North Carolina
Wake Forest Health
Winston-Salem, North Carolina
Ohio State University, James Cancer Center
Columbus, Ohio
Toledo Clinic Cancer Center
Toledo, Ohio
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.